Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01045382
Other study ID # TJB0909
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date July 2010
Est. completion date August 2021

Study information

Verified date August 2021
Source University of Liege
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present project aims at evaluating the capacity of MSC to improve one-year overall survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors after non-myeloablative conditioning. Co-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC) in an immunodeficient mouse model. In addition, it has been shown that infusion of third party MSC in HSC transplantation could be successfully used as treatment for grade II-IV steroid-refractory acute graft versus host disease. One hundred and twenty patients with HLA-mismatched donors will be included over 6 years at multiple centers across Belgium through the transplant committee of the Belgian Hematological Society. The conditioning regimen will consist of fludarabine and 2 Gy TBI, followed by the infusion of donor HSC. Patients will be randomized 1/1 in double-blind fashion to receive or not MSC (1.5-.3.0 x106/kg) from third-party (either haploidentical family members or unrelated volunteer) donors on day 0. Postgrafting immunosuppression will combine tacrolimus and MMF. Except for the collection, expansion and infusion of MSC, the clinical management of the patient will not differ from that of routine NM-HCT.


Recruitment information / eligibility

Status Terminated
Enrollment 39
Est. completion date August 2021
Est. primary completion date August 2021
Accepts healthy volunteers No
Gender All
Age group N/A to 75 Years
Eligibility Inclusion Criteria: - Theoretical indication for a standard allo-transplant, but not feasible because: Age > 55 yrs. Unacceptable end organ performance. Patient's refusal. - Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant. - Male or female; fertile female patients must use a reliable contraception method - Age = 75 year old - Informed consent given by patient or his/her guardian if of minor age. - One or two HLA mismatches with PBSC: - One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1 - Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1 - One antigenic mismatch: 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1. - One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C or -DRB1 - Patients with one single allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1 can also be included in the protocol. - Hematological malignancies confirmed histologically and not rapidly progressing: - AML in complete remission - ALL in complete remission - CML unresponsive/intolerant to Imatinib but not in blast crisis - Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis - MDS with <5% blasts - Multiple myeloma not rapidly progressing - CLL - Non-Hodgkin's lymphoma (aggressive NHL should be chemosensitive) - Hodgkin's disease Exclusion Criteria: - Any condition not fulfilling inclusion criteria - HIV positive - Terminal organ failure, except for renal failure (dialysis acceptable) - Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction <35%; uncontrolled arrhythmia; uncontrolled hypertension - Pulmonary: DLCO < 35% and/or receiving supplementary continuous oxygen - Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease - Uncontrolled infection, arrhythmia or hypertension - Previous radiation therapy precluding the use of 2 Gy TBI - 10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC.

Study Design


Intervention

Biological:
Mesenchymal stem cells
Mesenchymal stem cell injection
Other:
Isotonic solution
Isotonic solution injection

Locations

Country Name City State
Belgium Hôpital Stuyvenberg Antwerpen
Belgium AZ St-Jan Brugge Flanders West
Belgium Bordet Institute Brussels
Belgium St-Luc UCL Brussels Brabant
Belgium Vrije Universiteit Brussel Brussels
Belgium UZA Edeghem Antwerpen
Belgium UZ Gent Gent Flanders Ost
Belgium AZ Gasthuisberg Leuven Leuven Flamish Brabant
Belgium CHU-ULg Liège
Belgium Cliniques Universitaires Mont-Godinne Yvoir Namur

Sponsors (8)

Lead Sponsor Collaborator
University of Liege AZ Sint-Jan AV, AZ-VUB, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Jules Bordet Institute, Universiteit Antwerpen, University Hospital, Ghent, Ziekenhuis Netwerk Antwerpen (ZNA)

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary One-year overall survival in the 2 arms. One year
Secondary Incidence of grade II-IV and grade III-IV acute GVDH 100 days
Secondary Number of absolute donor T cells after HCT in each arm 28
Secondary Cumulative incidence of non-relapse mortality 100, 365 and 730 days
Secondary Incidence of extensive chronic GVHD in each arm 365 days
Secondary Incidence of graft rejection in each arm. 365 days
Secondary Quality and timing of immunologic reconstitution in each arm. 100, 365 and 730 days
Secondary Detection of MSC from donor origin in recipient marrow after HCT in patients given MSC 40 days
Secondary Proportion of patients with measurable disease at HCT who achieve a complete response in each arm. 100, 365 and 730 days
Secondary Cumulative incidence of relapse 365 and 730 days
Secondary Incidence of progression-free survival 365 and 730 days
Secondary Incidence of infections 100 days
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1